Neuromodulation News and Research

RSS

NeuroSigma gets approval to market Monarch eTNS System in Australia

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has received approval from the Therapeutic Goods Administration to market its Monarch eTNS System in Australia.

1 Apr 2014

Axonics Modulation Technologies completes $32.6 million Series A preferred stock financing

Axonics Modulation Technologies, Inc., a developer of novel implantable neuromodulation technology, announced today that it has completed a $32.6 million Series A preferred stock financing.

25 Mar 2014

FDA approves Allure Quadra Cardiac Resynchronization Therapy Pacemaker

St. Jude Medical, Inc., a global medical device company, today announced approval from the U.S. Food and Drug Administration (FDA) for the Allure Quadra™ Cardiac Resynchronization Therapy Pacemaker (CRT-P), which provides additional pacing innovations for physicians to treat patients with heart failure.

24 Mar 2014

Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Mainstay Medical today announced that it has secured approval from Ethics Committees in Australia to start a clinical trial of ReActiv8, its innovative implantable neurostimulation device for the treatment of people with Chronic Low Back Pain (CLBP). Recruitment of subjects for the trial has commenced at three clinical sites in Australia.

10 Mar 2014

NAFC designates Beth Israel Deaconess Medical Center as Center of Excellence

The National Association For Continence has designated Beth Israel Deaconess Medical Center as a Center of Excellence: Continence Care. Anurag K. Das, MD; Roger Lefevre, MD; Janet Li, MD; and Deborah A. Nagle, MD are the principle physicians for this COE.

27 Feb 2014

Greatbatch announces results for fourth quarter and full-year ended 2014

Greatbatch, Inc., today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth for the full year 2013; 12% year over year improvement in adjusted operating income; and 19% improvement in adjusted diluted EPS over 2012.

25 Feb 2014

Ablative Solutions completes $9.5M Series B Preferred Stock financing

Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.

4 Feb 2014

St. Jude Medical reports net sales of $1.422 billion in fourth quarter 2013

St. Jude Medical, Inc. today reported sales and net earnings for the fourth quarter and full year ended Dec. 28, 2013.

22 Jan 2014

St. Jude Medical evaluates effectiveness of PNfS and SCS for chronic low back and leg pain

St. Jude Medical, Inc., a global medical device company, has launched a clinical study to evaluate the combination of peripheral nerve field stimulation, and spinal cord stimulation, to determine whether the two therapies together offer more effective management of chronic low back and leg pain than SCS alone. The first patient in the SENSE Subcutaneous and Epidural Neuromodulation System Evaluation study was enrolled by Dr. Thomas Yearwood, an interventional pain physician at Comprehensive Pain & Rehabilitation in Pascagoula, Miss.

5 Dec 2013

Update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation procedures

Uroplasty, Inc. a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

4 Dec 2013

Sacral neuromodulation stands test of time in LUTD

Follow-up of patients at a Belgian institution reveals that sacral neuromodulation is effective for the treatment of lower urinary tract dysfunction over the long term, but often requires reintervention.

From Medtronic 25 Nov 2013

Vagus nerve stimulation-tone therapy safe for treating tinnitus, say UT Dallas researchers

UT Dallas researchers have demonstrated that treating tinnitus, or ringing in the ears, using vagus nerve stimulation-tone therapy is safe and brought significant improvement to some of the participants in a small clinical trial.

21 Nov 2013

Zale Lipshy University Hospital receives 2013 Press Ganey Beacon of Excellence Award

Zale Lipshy University Hospital at UT Southwestern Medical Center received the 2013 Press Ganey Beacon of Excellence Award for patient satisfaction, one of only three academic medical centers in the nation and one of 26 health care facilities selected nationally to receive that distinction.

21 Nov 2013

Boston Scientific gets CE Mark approval for Vercise Deep Brain Stimulation System

The Boston Scientific Corporation Vercise Deep Brain Stimulation System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions.

19 Nov 2013

Multidisciplinary team tests innovative heart failure therapy in global clinical trials

A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.

30 Oct 2013

Neuropsychoanalysis Association to host conference on depression

The Neuropsychoanalysis Association is hosting a conference for researchers and clinicians on depression, "Towards a Real Understanding of Depression: Lessons from the Treatment Battlefeld and New Research," on Friday, November 1, 2013 from 9:00 am to 6:00 pm at the Icahn School of Medicine at Mount Sinai, The Bonnie and Kenneth Davis Auditorium, 1470 Madison Avenue (between 101st and 102nd Streets) in New York City.

24 Oct 2013

A window to the brain: an interview with Professor Guillermo Aguilar, UC Riverside's Bourns College of Engineering (BCOE)

It is literally a transparent window made of yttria-stabilized zirconia (YSZ), which we envision to become a suitable cranial implant that allows physicians for optical access to the tissue brain. It would serve the same mechanical function of current cranial implants made of other materials, such as titanium, except that it would enable optical access too, which could be very beneficial for post-operatory diagnostic or therapeutic procedures.

8 Oct 2013

European launch of new version of REVIVE™ SE Thrombectomy Device for treatment of acute ischemic stroke announced by Codman Neuro

Codman Neuro*, part of DePuy Synthes Companies of Johnson & Johnson, announced the European launch of the REVIVE™ SE Thrombectomy Device, a next generation clot removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke.

9 Sep 2013

Researchers develop novel transparent skull implant that provides a window to the brain

A team of University of California, Riverside researchers have developed a novel transparent skull implant that literally provides a "window to the brain", which they hope will eventually open new treatment options for patients with life-threatening neurological disorders, such as brain cancer and traumatic brain injury.

4 Sep 2013

BIDMC receives grant to study new noninvasive neurophysiologic intervention for spinal cord injuries

Beth Israel Deaconess Medical Center has been awarded a grant from the National Institutes of Health to investigate the use of a new noninvasive neurophysiologic intervention for the treatment of patients with spinal cord injuries.